BAY 73-1449 is a selective prostacyclin receptor (IP) antagonist (inhibitor) with high potency (IC50 less than 0.1 nM) in cAMP assays in human HEL cells and rat DRG. BAY 73-1449 may be used in studies to lower blood pressure.

Physicochemical Properties

Molecular Formula	C26H23N3O3
Molecular Weight	425.47912
Exact Mass	425.173
CAS #	693790-96-4
PubChem CID	9910289
Appearance	White to off-white solid powder
LogP	5.2
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	9
Heavy Atom Count	32
Complexity	555
Defined Atom Stereocenter Count	1
SMILES	C1(COC2C=CC(C3N=CN=C(NC(C(O)=O)CC4C=CC=CC=4)C=3)=CC=2)C=CC=CC=1
InChi Key	RRYFPNITZGCUPZ-XMMPIXPASA-N
InChi Code	InChI=1S/C26H23N3O3/c30-26(31)24(15-19-7-3-1-4-8-19)29-25-16-23(27-18-28-25)21-11-13-22(14-12-21)32-17-20-9-5-2-6-10-20/h1-14,16,18,24H,15,17H2,(H,30,31)(H,27,28,29)/t24-/m1/s1
Chemical Name	(2R)-3-phenyl-2-[[6-(4-phenylmethoxyphenyl)pyrimidin-4-yl]amino]propanoic acid
Synonyms	BAY-73-1449 BAY 73-1449 BAY73-1449
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	In rats, BAY 73-1449 (0.1–1 mg/kg; iv) significantly lowers splenic shunt channel outflow but not mesenteric inflow [1]. On the degree of portosystemic shunting in rats, BAY 73-1449 (1–5 mg/kg, subcutaneous injection, once daily, for 7 days) shows no effect [1]. Rats' portal pressure is unaffected by BAY 73-1449 (1 mg/kg, subcutaneous injection once daily for 7 days) [1].
Animal Protocol	Animal/Disease Models: Male Wistar rats (250-350 g) with portal vein ligation [1] Doses: 0.1, 1 mg/kg Route of Administration: Single intravenous (iv) (iv)injection Experimental Results: Dramatically diminished shunt blood flow without affecting mesenteric blood flow.
References	[1]. Vascular actions of the prostacyclin receptor antagonist BAY 73-1449 in the portal hypertensive rat. Eur J Pharmacol. 2008 Aug 20;590(1-3):322-6.

Solubility Data

Solubility (In Vitro)

DMSO : ~250 mg/mL (~587.57 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 2.08 mg/mL (4.89 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.89 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.3503 mL	11.7514 mL	23.5029 mL
	5 mM	0.4701 mL	2.3503 mL	4.7006 mL
	10 mM	0.2350 mL	1.1751 mL	2.3503 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.